[CAS NO. 188860-26-6] DMA
PRODUCTS SPECIFICATIONS [188860-26-6]
DESCRIPTION [188860-26-6]
Overview
| MDL | MFCD26143176 |
|---|---|
| Molecular Weight | 468.55 |
| Molecular Formula | C27H28N6O2 |
| SMILES | CN1CCN(C2=CC=C3C(N=C(C4=CC=C5C(N=C(C6=CC=C(OC)C(OC)=C6)N5)=C4)N3)=C2)CC1 |
Summary
DMA is a fluorescent compound (λ ex =340 nm, λ em =478 nm).
IC50 & Target
IC50: 3.4 μM (HeLa cell), 5.3 μM (MCF7 cell) [1]
In Vitro
The newly synthesized bisbenzimidazole derivatives DMA (6c) is evaluated for their cytotoxicity against human tumor cell lines, which are cervix carcinoma cell line (HeLa), breast carcinoma cell line (MCF7) and brain glioma cell line (U87) in comparison to Hoechst. In case of MCF7, the IC 50 is observed at 5.3 μM for DMA. The IC 50 determined in the case of HeLa is 3.4 μM for DMA [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT05524519 | The Third Affiliated hospital of Zhejiang Chinese Medical University|Zhejiang Provincial Tongde Hospital|First People´s Hospital of Hangzhou |
Major Depressive Disorder
|
January 1, 2022 | Not Applicable |
| NCT04413357 | Nestlé |
Diabetes Mellitus, Type 2
|
May 18, 2020 | Not Applicable |
| NCT04296201 | Lumenis Be Ltd. |
Skin Laxity|Muscle Contracture
|
September 1, 2020 | Not Applicable |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 54 mg/mL ( 115.25 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1342 mL | 10.6712 mL | 21.3424 mL |
| 5 mM | 0.4268 mL | 2.1342 mL | 4.2685 mL |
| 10 mM | 0.2134 mL | 1.0671 mL | 2.1342 mL |
